Achieving the composite end ‐point of glycated hemoglobin < 7.0% without weight gain or hypoglycemia with once ‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis

ConclusionsDulaglutide is found to be an effective therapeutic alternative for Chinese type  2 diabetes patients. Compared with GLIM/GLAR, significantly greater proportions of patients on DU attained the HbA1c target of<7.0% without weight gain or hypoglycemia.

Source: Journal of Diabetes Investigation - January 2, 2020 Category: Endocrinology Authors: Xinhua Xiao, Changjiang Wang, Xiaoyang Lai, Bin Zhang, Liqun Gu, Jianing Hou, Zhiguang Zhou Tags: Clinical Trial Source Type: research